Profile data is unavailable for this security.
About the company
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
- Revenue in USD (TTM)0.00
- Net income in USD-64.20m
- Incorporated2018
- Employees9.00
- LocationClimb Bio Inc20 WILLIAM STREET, SUITE 145WELLESLEY HILLS 02481United StatesUSA
- Phone+1 (425) 276-2300
- Fax+1 (302) 636-5454
- Websitehttps://climbbio.com/
More ▼
Mergers & acquisitions
| Acquired company | CLYM:NMQ since announced | Transaction value |
|---|---|---|
| Tenet Medicines Inc | 32.21% | -- |
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | 93.14m | -168.30m | 241.14m | 137.00 | -- | 4.94 | -- | 2.59 | -0.8371 | -0.8371 | 0.4634 | 0.265 | 0.2483 | 3.96 | 84.52 | 679,832.10 | -44.87 | -31.02 | -53.39 | -34.63 | 67.80 | 78.04 | -180.70 | -372.21 | 4.24 | -15.53 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 241.54m | 59.00 | -- | 2.91 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.24m | 246.28m | 32.00 | -- | 1.69 | -- | 289.75 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Omeros Corp | 0.00 | -199.92m | 246.85m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Editas Medicine Inc | 61.76m | -210.57m | 253.42m | 265.00 | -- | 1.44 | -- | 4.10 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Lexeo Therapeutics Inc | 0.00 | -77.22m | 254.24m | 58.00 | -- | 1.54 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -64.20m | 254.83m | 9.00 | -- | 1.14 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| MacroGenics Inc | 141.33m | -97.62m | 257.33m | 339.00 | -- | 2.14 | -- | 1.82 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Acrivon Therapeutics Inc | 0.00 | -69.00m | 259.86m | 58.00 | -- | 1.20 | -- | -- | -2.77 | -2.77 | 0.00 | 6.98 | 0.00 | -- | -- | 0.00 | -35.33 | -- | -37.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 263.81m | 168.00 | -- | 0.6895 | -- | 6.50 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Abeona Therapeutics Inc | 0.00 | -52.60m | 264.43m | 84.00 | -- | 3.47 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Kodiak Sciences Inc | 0.00 | -197.68m | 267.28m | 111.00 | -- | 1.25 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Mersana Therapeutics Inc | 29.94m | -104.77m | 269.89m | 123.00 | -- | 32.03 | -- | 9.02 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 271.03m | 181.00 | -- | 0.6826 | -- | 22.00 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Data as of Nov 13 2024. Currency figures normalised to Climb Bio Inc's reporting currency: US Dollar USD
63.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 31.42m | 46.85% |
| Deep Track Capital LPas of 02 Jul 2024 | 3.90m | 5.82% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 3.25m | 4.85% |
| Affinity Asset Advisors LLCas of 14 Aug 2024 | 1.81m | 2.70% |
| Driehaus Capital Management LLCas of 30 Jun 2024 | 696.06k | 1.04% |
| Adage Capital Management LPas of 30 Jun 2024 | 670.36k | 1.00% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 343.71k | 0.51% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 318.58k | 0.48% |
| Sphera Funds Management Ltd.as of 30 Jun 2024 | 215.18k | 0.32% |
| Walleye Capital LLCas of 30 Jun 2024 | 196.39k | 0.29% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
